Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/62052
DC Field | Value | Language |
---|---|---|
dc.contributor | Department of Health Technology and Informatics | - |
dc.creator | Supriya, R | - |
dc.creator | Tam, BT | - |
dc.creator | Pei, XM | - |
dc.creator | Lai, CW | - |
dc.creator | Chan, LW | - |
dc.creator | Yung, BY | - |
dc.creator | Siu, PM | - |
dc.date.accessioned | 2016-12-19T08:58:21Z | - |
dc.date.available | 2016-12-19T08:58:21Z | - |
dc.identifier.uri | http://hdl.handle.net/10397/62052 | - |
dc.language.iso | en | en_US |
dc.publisher | Frontiers Research Foundation | en_US |
dc.rights | Copyright © 2016 Supriya, Tam, Pei, Lai, Chan, Yung and Siu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | en_US |
dc.rights | The following publication Supriya R, Tam BT, Pei XM, Lai CW, Chan LW, Yung BY and Siu PM (2016) Doxorubicin Induces Inflammatory Modulation and Metabolic Dysregulation in Diabetic Skeletal Muscle. Front. Physiol. 7:323,1-13 is available at https://dx.doi.org/10.3389/fphys.2016.00323 | en_US |
dc.subject | Anaerobic glycolysis | en_US |
dc.subject | Anti-inflammation | en_US |
dc.subject | Cancer chemotherapy | en_US |
dc.subject | Myotoxicity | en_US |
dc.subject | Pro-inflammation | en_US |
dc.subject | Type 2 diabetes mellitus | en_US |
dc.title | Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle | en_US |
dc.type | Journal/Magazine Article | en_US |
dc.identifier.spage | 1 | en_US |
dc.identifier.epage | 13 | en_US |
dc.identifier.volume | 7 | en_US |
dc.identifier.doi | 10.3389/fphys.2016.00323 | en_US |
dcterms.abstract | Anti-cancer agent doxorubicin (DOX) has been demonstrated to worsen insulin signaling, engender muscle atrophy, trigger pro-inflammation, and induce a shift to anaerobic glycolytic metabolism in skeletal muscle. The myotoxicity of DOX in diabetic skeletal muscle remains largely unclear. This study examined the effects of DOX on insulin signaling, muscle atrophy, pro-/anti-inflammatory microenvironment, and glycolysis metabolic regulation in skeletal muscle of db/db diabetic and db/+ non-diabetic mice. Non-diabetic db/+ mice and diabetic db/db mice were randomly assigned to the following groups: db/+CON, db/+DOX, db/dbCON, and db/dbDOX. Mice in db/+DOX and db/dbDOX groups were intraperitoneally injected with DOX at a dose of 15 mg per kg body weight whereas mice in db/+CON and db/dbCON groups were injected with the same volume of saline instead of DOX. Gastrocnemius was immediately harvested, weighed, washed with cold phosphate buffered saline, frozen in liquid nitrogen, and stored at -80°C for later analysis. The effects of DOX on diabetic muscle were neither seen in insulin signaling markers (Glut4, pIRS1Ser636/639, and pAktSer473) nor muscle atrophy markers (muscle mass, MuRF1 and MAFbx). However, DOX exposure resulted in enhancement of pro-inflammatory favoring microenvironment (as indicated by TNF-α, HIFα and pNFκBp65) accompanied by diminution of anti-inflammatory favoring microenvironment (as indicated by IL15, PGC1a and pAMPKß1Ser108). Metabolism of diabetic muscle was shifted to anaerobic glycolysis after DOX exposure as demonstrated by our analyses of PDK4, LDH and pACCSer79. Our results demonstrated that there might be a link between inflammatory modulation and the dysregulation of aerobic glycolytic metabolism in DOX-injured diabetic skeletal muscle. These findings help to understand the pathogenesis of DOX-induced myotoxicity in diabetic muscle. | - |
dcterms.accessRights | open access | en_US |
dcterms.bibliographicCitation | Frontiers in physiology, 27 July 2016, v. 7, 323, p. 1-13 | - |
dcterms.isPartOf | Frontiers in physiology | - |
dcterms.issued | 2016-07-27 | - |
dc.identifier.isi | WOS:000380314400001 | - |
dc.identifier.scopus | 2-s2.0-84981525092 | - |
dc.identifier.pmid | 27512375 | - |
dc.identifier.ros | 2016000202 | - |
dc.identifier.eissn | 1664-042X | en_US |
dc.identifier.artn | 323 | en_US |
dc.identifier.rosgroupid | 2016000201 | - |
dc.description.ros | 2016-2017 > Academic research: refereed > Publication in refereed journal | en_US |
dc.description.validate | 201804_a bcma | en_US |
dc.description.oa | Version of Record | en_US |
dc.identifier.FolderNumber | OA_IR/PIRA | en_US |
dc.description.pubStatus | Published | en_US |
Appears in Collections: | Journal/Magazine Article |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Supriya_Doxorubicin_Inflammatory_Modulation.pdf | 3.72 MB | Adobe PDF | View/Open |
Page views
131
Last Week
1
1
Last month
Citations as of Mar 24, 2024
Downloads
74
Citations as of Mar 24, 2024
SCOPUSTM
Citations
23
Last Week
1
1
Last month
Citations as of Mar 28, 2024
WEB OF SCIENCETM
Citations
21
Last Week
0
0
Last month
Citations as of Mar 28, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.